Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells

Immunology and Cell Biology

Volumn 88, Issue 6, 2010, Pages 676-684

  Nguyen, Thi H O ^a,b   Sullivan, Lucy C ^c   Kotsimbos, Tom C ^a,d   Schwarer, Anthony P ^a,b   Mifsud, Nicole A ^d  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

human cytomegalovirus; IE1 pp65 protein; immunodominance hierarchy

Indexed keywords

CHIMERIC PROTEIN; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NORMAL HUMAN;

CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MONOCYTES; PHOSPHOPROTEINS; PROTEIN BINDING; RECOMBINANT PROTEINS; VIRAL MATRIX PROTEINS; VIRUS ACTIVATION;

HUMAN HERPESVIRUS 5;

EID: 77955657493     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.20     Document Type: Article

References (50)

1. Pass RF. Epidemiology and transmission of cytomegalovirus. J Infect Dis 1985; 152: 243-248.
2. Zaia JA, Sissons JG, Riddell S, Diamond DJ, Wills MR, Carmichael AJ et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology (Am Soc Hematol Educ Program) 2000, 339-355.
3. Hebart H, Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 2004; 65: 432-436.
4. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377.
5. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-4406.
6. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 2000; (Suppl) T3, 35-43
7. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
8. van Rhee F, Barrett J. Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation. Cytotherapy 2002; 4: 3-10.
9. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386.
10. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922.
11. Micklethwaite K, Hansen A, Foster A, Snape E, Antonenas V, Sartor M et al. Ex vivo expansion and prophylactic infusion of CMV-pp peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 707-714.
12. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226-5240.
13. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725-738.
14. Vaz-Santiago J, Lule J, Rohrlich P, Jacquier C, Gibert N, Le Roy E et al. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 2001; 75: 7840-7847.
15. Vaz-Santiago J, Lule J, Rohrlich P, Kravtzoff R, Le Roy E, Davignon JL et al. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy. Cytotherapy 2002; 4: 11-19.
16. Einsele H, Rauser G, Grigoleit U, Hebart H, Sinzger C, Riegler S et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy 2002; 4: 49-54.
17. Hobeika A, Osada T, Serra D, Peplinski S, Hanson K, Tanaka Y et al. Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy 2008; 10: 289-302.
18. Sacre K, Nguyen S, Deback C, Carcelain G, Vernant JP, Leblond V et al. Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol 2008; 82: 10143-10152.
19. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673-685.
20. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974-3981.
21. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
22. Yewdell JW. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006; 25: 533-543.
23. Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, Martinez J et al. Relative dominance of HLA-B restricted CD8(+) T-Lymphocyte immune responses to human cytomegalovirus pp in persons sharing HLA-A and HLA-B alleles. Hum Immunol 2003; 64: 440-452.
24. Heine A, Grunebach F, Holderried T, Appel S, Weck MM, Dorfel D et al. Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. Mol Ther 2006; 13: 280-288.
25. Nguyen TH, Mifsud NA, Stewart LA, Rose MJ, Etto TL, Williamson NA et al. Refinement in the production and purification of recombinant HCMV IE1-pp protein for the generation of epitope-specific T cell immunity. Protein Expr Purif 2008; 61: 22-30.
26. Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002; 99: 3830-3837.
27. Khan N, Best D, Bruton R, Nayak L, Rickinson AB, Moss PA. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007; 178: 4455-4465.
28. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ et al. Cytomegalovirus seropositivity drives the CD T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984-1992.
29. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685-1696.
30. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD T cells by CD8- dendritic cells, but cross-presented to CD T cells by CD8+ dendritic cells. J Immunol 2001; 166: 5327-5330.
31. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR. Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 1998; 19: 368-373.
32. Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM et al. Crosspresentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine 2006; 24: 6272-6281.
33. Dunbar E, Alatery A, Basta S. Cross-priming of a single viral protein from lymphocytic choriomeningitis virus alters immunodominance hierarchies of CD8+ T cells during subsequent viral infections. Viral Immunol 2007; 20: 585-598.
34. Tabi Z, Moutaftsi M, Borysiewicz LK. Human cytomegalovirus pp65- and immediate early antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. J Immunol 2001; 166: 5695-5703.
35. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001; 97: 994-1000.
36. Scheller N, Furtwangler R, Sester U, Maier R, Breinig T, Meyerhans A. Human cytomegalovirus protein pp65: an efficient protein carrier system into human dendritic cells. Gene Ther 2008; 15: 318-325.
37. Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176: 4094-4101.
38. Hollsberg P. Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus. Scand J Immunol 2002; 55: 189-195.
39. Mifsud NA, Purcell AW, Chen W, Holdsworth R, Tait BD, McCluskey J. Immunodominance hierarchies and gender bias in direct T(CD8)-cell alloreactivity. Am J Transplant 2008; 8: 121-132.
40. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997; 64: 1017-1027.
41. Burrows JM, Wynn KK, Tynan FE, Archbold J, Miles JJ, Bell MJ et al. The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur J Immunol 2007; 37: 946-953.
42. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771.
43. Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000; 12: 83-93.
44. Longmate J, York J, La Rosa C, Krishnan R, Zhang M, Senitzer D et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 2001; 52: 165-173.
45. Retiere C, Prodhomme V, Imbert-Marcille BM, Bonneville M, Vie H, Hallet MM. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp or IE proteins: a tool to study the fine specificity of the antiviral response. J Virol 2000; 74: 3948-3952.
46. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70: 7569-7579.
47. Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, Schonemann C et al. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999; 73: 8179-8184.
48. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000; 405: 537-543.
49. Sullivan LC, Clements CS, Beddoe T, Johnson D, Hoare HL, Lin J et al. The heterodimeric assembly of the CD94-NKG receptor family and implications for human leukocyte antigen-E recognition. Immunity 2007; 27: 900-911.
50. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide- MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000; 165: 6229-6234.